Physician profile
Manuel E Rodriguez
NPI 1356399307
$105,709.52
in general payments reported to CMS, 2019-2025
46 companies · $40K in 2025
The $40K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $922 · 2020: $103 · 2021: $426 · 2022: $1,262 · 2023: $762 · 2024: $62K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $86K · Travel and Lodging: $9,410 · Food and Beverage: $6,597 · Consulting Fee: $968 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $85,999.50 |
| Travel and Lodging | $9,410.16 |
| Food and Beverage | $6,597.21 |
| Consulting Fee | $967.50 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $57,155.85 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $42,879.02 | 2021-2025 | Livdelzi |
| Abbvie INC. | $2,229.10 | 2019-2025 | Linzess, Creon, Viberzi |
| Janssen Biotech, INC. | $301.24 | 2019-2025 | Simponi, Stelara, Simponi Aria |
| Phathom Pharmaceuticals, INC. | $271.87 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $238.87 | 2025 | |
| Aimmune Therapeutics, INC. | $217.74 | 2024-2025 | Vowst, Zenpep |
| Intercept Pharmaceuticals, INC. | $194.12 | 2019-2023 | Ocaliva |
| Lilly USA, LLC | $188.95 | 2024-2025 | Omvoh |
| Qol Medical, LLC | $184.42 | 2019-2025 | Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $157.12 | 2020-2023 | Entyvio |
| Pfizer INC. | $156.19 | 2019 | |
| Celgene Corporation | $148.15 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $141.15 | 2021-2024 | Dificid, Zinplava |
| Regeneron Healthcare Solutions, INC. | $129.66 | 2023-2024 | Dupixent |
Show all 41 companies
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.